课题基金 / 基金详情

THE MECHANISM OF REDUCTION OF TOXIC CHEMICALS AND DRUGS

THE MECHANISM OF REDUCTION OF TOXIC CHEMICALS AND DRUGS
减少有毒化学品和药物的机制
批准号:
3855932
负责人:
R P MASON
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

R P MASON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The first step in metabolic conversion of many chemicals and toxic drugs is the reduction of the parent compound to give a free radical intermediate. This metabolism has been shown to occur in both liver microsomes and hepatocytes. For nitroheterocyclic drugs, the nitro group is reduced to the corresponding nitro radical anion and for bipyridylium dications, the parent compound is reduced to the bipyridylium radical monocation. By judicious application of paramagnetic line broadening agents, we have shown that the radicals, initially formed inside the cell can freely cross the plasma membrane, and the EPR signal detected is mainly due to radical present extracellularly. Recently, the laboratory purchased a Krumdieck tissue slicer. This type of slicer has been shown to produced reproducibly thin slices with maximal slice integrity. Liver slices, unlike microsomes or hepatocytes, contain a cross section of all liver cells and the results are more physiologically similar to in vivo liver metabolism. This is the first such EPR application to organ slices which have not been lyophilized or encased in paraffin supports. Preliminary experiments with bipyridylium dictations have shown that it is possible to-detect free radical intermediates in thin liver slices and that the radical generated is in a more viscous environment than with either microsomes or hepatocytes. In the coming year, we will continue this line of investigation and extend the experiments to include nitoheterocyclic compounds.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHENYL RADICAL FORMATION BY OXYHEMOGLOBIN FROM PHENYLHYDRAZINE IN VIVO
RELATIONSHIP OF FREE RADICALS TO HALOCARBON-INDUCED TOXICITY IN THE LIVER
RADICAL ANION METABOLITES
REACTION OF FREE RADICAL METABOLITES WITH DNA
海外基金